Basic science: (April 2009)

Abstract

1. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69: 3589–3596. 2. Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009; 10: 381–390. 3. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S. Association of estrogen receptor a and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009; 69: 2935–2940. 4. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 2009; 124: 1756–1766. 5. Cardamone MD, Bardella C, Gutierrez A, Croce LD, Rosenfeld MG, Di Renzo MF, De Bortoli M. ERa as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 7420–7425. 6. Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh MC, Chen CL, Yang RB. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res 2009; 69: 3634–3641. 7. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, Mauro L, Fuqua SAW, Ando S. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor a gene promoter. Mol Endocrinol 2009; 23: 454–465. 8. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 2009; 69: 2817–2825. 9. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15: 2472–2478. 10. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RKR, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009; 124: 1552–1564. 11. Kataoka M, Antoniou A, Warren R, Leyland J, Brown J, Audley T, Easton D. Genetic models for the familial aggregation of mammographic breast density. Cancer Epidemiol Biomarkers Prev 2009; 18: 1277–1284. 12. Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27(Kip1) phosphorylation on Thr187 and accumulates p27(Kip1) in the nucleus: implications for breast cancer therapy. Mol Cell Biol 2009; 29: 2254–2263. 13. Kwek SS, Roy R, Zhou H, Climent J, MartinezCliment JA, Fridlyand J, Albertson DG. Coamplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28: 1892–1903. 14. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 2009; 174: 1172–1190. 15. Millar EKA, Dean JL, McNeil CM, O’Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CES, Witkiewicz A, Musgrove EA, Rui H, LeMarchand L, Setiawan VW, Haiman CA, First published online 14/07/09 BCO/853/2009/JW